Skip to main content
SpringerLink
Log in

Quality of Life in Dermatology

  • Chapter
  • First Online:
Dermatology in Public Health Environments

  • 755 Accesses

Abstract

Dermatoses may have an important powerful effect on patients’ social, family, and professional life. Besides the objective evaluation of therapeutic results, the influence of diseases on patients’ quality of life, by way of confirmed questionnaires, is also considered relevant, even though the majority of dermatologic patients do not have a life-threatening illness but only suffer from the social stigma because of clear evidence of dermatoses.

The terms health, health-related quality of life (HRQoL), and quality of life (QoL) are used as synonyms. But, given that these are three key terms in the literature, their appropriate and clear concept is important.

Definition of health was provided by the World Health Organization as “a state of complete physical, mental, and social well-being, and not merely the absence of disease and infirmity.”

QoL definition is challenging, and there are many approaches to define it. There are approaches based on human needs, subjective well-being, expectations, and phenomenological viewpoints. One of the more used in literature is: “QoL is a conscious cognitive judgment of satisfaction with one’s life and an individuals’ perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns.”

Health-related QoL is a multidimensional concept that reflects patients’ subjective evaluation of the effects of a disease and its treatment on their psychologic and physical well-being and their social functioning.

In the last decade, there has been a growing interest in the development of methodologies to measure the QoL of dermatology patients and oncology patients and the literature on QoL has increased exponentially. A MEDLINE search for QoL in a title between 1982 and 1988 revealed 618 articles, whereas between 1996 and 2002, 5951 such articles were found. Besides, a PubMed search for QoL and dermatology in a title between 1996 and 2021 revealed 1080 articles.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

QoL:

Quality of life

WHO:

World Health Organization

References

  1. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272(8):619–26.

    Article  CAS  PubMed  Google Scholar 

  2. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622–9.

    Article  CAS  PubMed  Google Scholar 

  3. The WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;10:1403–9.

    Google Scholar 

  4. World Health Organization. Constitution of the World Health Organization. 48th ed. Geneva: Basic Documents of the World Health Organization; 2014.

    Google Scholar 

  5. Weber MB, Mazzotti NG, Prati C, Cestari TF. Quality of life assessment in the overall evaluation of dermatology patients. HCPA. 2006;26(2):35–44.

    Google Scholar 

  6. Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.

    Article  CAS  PubMed  Google Scholar 

  7. Madhulika A, Aditya K. Psychodermatology: an update. J Am Acad Adermatol. 1996;34:1030–46.

    Article  Google Scholar 

  8. Folks DG, Warnock JK. Psychocutaneous disorders. Curr Psychiatry Rep. 2001;3:219–25.

    Article  CAS  PubMed  Google Scholar 

  9. Walker C, Papadopoulos L. Psychodermatology: the psychological impact of skin disorders. New York, Cambridge University Press, 2005. JAMA. 2007;297:97–8.

    Google Scholar 

  10. Tucker P, et al. The psychosocial impact of alopecia areata. J Health Psychol. 2009;14(1):142–51.

    Article  PubMed  Google Scholar 

  11. Manzoni APDS, Weber MB, Nagatomi ARS, Pereira RL, Townsend RZ, Cestari TF. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol. 2013;88:894.

    Article  PubMed  Google Scholar 

  12. Gaspar T, et al. Qualidade de vida e bem-estar em crianças e adolescentes. Rev Bras Ter Cogn Dez. 2006;2(2):47–60. ISSN: 1808-5687

    Google Scholar 

  13. Chren MM. Measurement of vital signs for skin diseases. J Invest Dermatol 2005;125(4):viii–x.

    Google Scholar 

  14. Finlay AY. Quality of life in dermatology: after 125 years, time for more rigorous reporting. Br J Dermatol. 2014;170:4–6.

    Article  CAS  PubMed  Google Scholar 

  15. Haraldstad K, Wahl A, Andenæs R, Andersen JR, Andersen MH, et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res [Internet]. 2019;28(10):2641–50. https://doi.org/10.1007/s11136-019-02214-9.

    Article  CAS  PubMed  Google Scholar 

  16. Cella D, Chang C-H, Lai J-S, Webster K. Advances in quality of life measurements in oncology patients. Seminars in Oncology [Internet]. 2002;29(3 Suppl 8):60–8. https://doi.org/10.1053/sonc.2002.33535.

    Article  PubMed  Google Scholar 

  17. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136(3):305–14.

    Article  CAS  PubMed  Google Scholar 

  18. Development of the World Health Organization WHOQOL-Bref quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28(3):551–8.

    Google Scholar 

  19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  20. Lindholm C, Bjellerup M, Christensen OB, Zederfeldt B. Quality of life in chronic leg ulcer patients. An assessment according to the Nottingham health profile. Acta Derm Venereol. 1993;73(6):440–3.

    CAS  PubMed  Google Scholar 

  21. Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65(12):1304–10.

    Article  CAS  PubMed  Google Scholar 

  22. Ruta DA, Garratt AM, Leng M, Russell IT, MacDonald LM. A new approach to the measurement of quality of life. The patient-generated index. Med Care. 1994;32(11):1109–26.

    Article  CAS  PubMed  Google Scholar 

  23. Fleck MPA, Louzada S, Xavier M, et al. Aplicação da versão em português do instrumento abreviado de avaliação da qualidade de vida “WHOQOLbref”. Rev Saude Publica. 2000;34(2):178–83.

    Article  CAS  PubMed  Google Scholar 

  24. Skoet R, Zachariae R, Agner T. Contact dermatitis and quality of life: a structured review of the literature. Br J Dermatol. 2003;149(3):452–6.

    Article  CAS  PubMed  Google Scholar 

  25. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure. Rev Bras Reumatol. 1999;39(3):143–50.

    Google Scholar 

  26. Teixeira-Salmela LF, Magalhães LC, Souza AC, Lima MC, Lima RCM, Goulart F. Adaptação do Perfil de Saúde de Nottingham: um instrumento simples de avaliação da qualidade de vida. Cad Saude Publica. 2004;20(4):905–14.

    Article  PubMed  Google Scholar 

  27. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19(8):787–805.

    Article  CAS  PubMed  Google Scholar 

  28. Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv. 1976;6(3):393–415.

    Article  CAS  PubMed  Google Scholar 

  29. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol. 1990;123(6):751–6.

    Article  CAS  PubMed  Google Scholar 

  30. Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Qual Life Res. 1996;5(1):131–8.

    Article  CAS  PubMed  Google Scholar 

  31. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol. 1993;129(4):422–30.

    Article  CAS  PubMed  Google Scholar 

  32. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol. 2000;39(11):801–6.

    Article  CAS  PubMed  Google Scholar 

  33. De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002;138(9):1221–7.

    Article  PubMed  Google Scholar 

  34. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–9.

    Article  CAS  PubMed  Google Scholar 

  35. Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, Finlay AY. The children’s dermatology life quality index: validation of the cartoon version. Br J Dermatol. 2003;148(2):285–90.

    Article  CAS  PubMed  Google Scholar 

  36. Lewis-Jones MS, Finlay AY, Dykes PJ. The infants’ dermatitis quality of life index. Br J Dermatol. 2001;144(1):104–10.

    Article  CAS  PubMed  Google Scholar 

  37. Hahn HB, Melfi CA, Chuang TY, et al. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol. 2001;45(1):44–8.

    Article  CAS  PubMed  Google Scholar 

  38. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–13.

    Article  CAS  PubMed  Google Scholar 

  39. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37(1):41–50.

    Article  CAS  PubMed  Google Scholar 

  40. Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol. 1995;133(4):575–8.

    Article  CAS  PubMed  Google Scholar 

  41. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141(4):698–702.

    Article  CAS  PubMed  Google Scholar 

  42. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80(6):430–4.

    Article  CAS  PubMed  Google Scholar 

  43. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health related quality of life. Int J Dermatol. 2002;41(3):151–8.

    Article  PubMed  Google Scholar 

  44. Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm Venereol. 2000;80(4):272–6.

    Article  CAS  PubMed  Google Scholar 

  45. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433–40.

    Article  CAS  PubMed  Google Scholar 

  46. Anderson R, Rajagopalan R. Responsiveness of the Dermatology-specific Quality of Life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res. 1998;7(8):723–34.

    Article  CAS  PubMed  Google Scholar 

  47. Finlay AY, Kelly SE. Psoriasis—an index of disability. Clin Exp Dermatol. 1987;12(1):8–11.

    Article  CAS  PubMed  Google Scholar 

  48. Gupta MA, Gupta AK. The psoriasis life stress inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75(3):240–3.

    CAS  PubMed  Google Scholar 

  49. McKenna SP, Cook SA, Whalley D, et al. Development of the PSORIQoL, a psoriasis specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003;149(2):323–31.

    Article  CAS  PubMed  Google Scholar 

  50. Chiricozzi A, Bianchi L, Zangrilli A, Bavetta M, Giunta A, Chimenti S, et al. Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. Eur J Dermatol [Internet]. 2015;25(1):64–9. https://doi.org/10.1684/ejd.2014.2473.

    Article  PubMed  Google Scholar 

  51. Ezzedine K, Fougerousse AC, Aubert R, Monfort J-B, Reguiaï Z, Shourick J, et al. Individual Burden of Psoriasis (I-BOP): Building and Validation of a New Scoring Tool for Patients with Psoriasis. CCID [Internet]. 2020;13:325–32. https://doi.org/10.2147/CCID.S249776.

    Article  PubMed  Google Scholar 

  52. Oakley AM. The acne disability index: usefulness confirmed. Australas J Dermatol. 1996;37(1):37–9.

    Article  CAS  PubMed  Google Scholar 

  53. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992;17(1):1–3.

    Article  CAS  PubMed  Google Scholar 

  54. Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne – assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26(5):380–5.

    Article  CAS  PubMed  Google Scholar 

  55. Fehnel SE, McLeod LD, Brandman J, et al. Responsiveness of the Acne-Specific Quality of Life Questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res. 2002;11(8):809–16.

    Article  CAS  PubMed  Google Scholar 

  56. Nicholson K, Abramova L, Chren M, Yeung J, Chon Y, Chen SC. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol Volume 57, Issue 2, August 2007, Pages 213–221.

    Google Scholar 

  57. McLellan C, Sisic M, Oon HH, Tan J. Preliminary validation of the HS-QoL: a quality-of-life measure for hidradenitis Suppurativa. J Cutan Med Surg. 2018;22(2):142–6.

    Article  PubMed  Google Scholar 

  58. Pinard J, Vleugels RA, Joyce C, Merola JF, Patel M. Hidradenitis suppurativa burden of disease tool: pilot testing of a disease-specific quality of life questionnaire. J Am Acad Dermatol. 2018;78(1):215–217.e2.

    Article  PubMed  Google Scholar 

  59. Thorlacius L, Esmann S, Miller I, Gregor V, Jemec GBE. Development of HiSQOL: a hidradenitis Suppurativa-specific quality of life instrument. Skin Appendage Disord. 2019;5:221–9.

    Article  PubMed  Google Scholar 

  60. Peris K, Lo Schiavo A, Fabbrocini G, Dini V, Patrizi A, Fusano M, et al. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol [Internet]. 2019;33(4):766–73. https://doi.org/10.1111/jdv.15425.

    Article  CAS  PubMed  Google Scholar 

  61. Şenol A, Yücelten AD, Ay P. Development of a quality of life scale for vitiligo. Dermatology. 2013;226(2):185–90. https://doi.org/10.1159/000348466. Epub 2013 May 28

    Article  PubMed  Google Scholar 

  62. Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11–8. https://doi.org/10.1016/j.jaad.2012.01.038. Epub 2012 Feb 25.

    Article  PubMed  Google Scholar 

  63. Gupta V, Sreenivas V, Mehta M, Khaitan BK, Ramam M. Measurement properties of the vitiligo impact scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. Br J Dermatol. 2014;171:1084–90.

    Article  CAS  PubMed  Google Scholar 

  64. Lieu TJ, Pandya AG. Melasma quality of life measures. Dermatol Clin. 2012;30(2):269–80., viii. https://doi.org/10.1016/j.det.2011.11.009.

    Article  CAS  PubMed  Google Scholar 

  65. Pollo CF, Miot LDB, Meneguin S, Miot HA. Development and validation of a multidimensional questionnaire for evaluating quality of life in melasma (HRQ-melasma). An Bras Dermatol [Internet]. 2018;93(3):391–6. https://doi.org/10.1590/abd1806-4841.20186780.

    Article  PubMed  Google Scholar 

  66. Chen SC, Yeung J, Chren MM. Scalpdex: a quality of life instrument for scalp dermatitis. Arch Dermatol. 2002;138(6):803–7.

    Article  PubMed  Google Scholar 

  67. Dolte KS, Girman CJ, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol [Internet]. 2000;25(8):637–42. https://doi.org/10.1046/j.1365-2230.2000.00726.x.

    Article  CAS  PubMed  Google Scholar 

  68. Fabbrocini G, Panariello L, De Vita V, Vincenzi C, Lauro C, Nappo D, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol [Internet]. 2012;27(3):e276–81. https://doi.org/10.1111/j.1468-3083.2012.04629.x.

    Article  PubMed  Google Scholar 

  69. Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol [Internet]. 2012;22(4):531–6. https://doi.org/10.1684/ejd.2012.1752.

    Article  PubMed  Google Scholar 

  70. Gabes M, Chamlin SL, Lai J-S, Cella D, Mancini AJ, Apfelbacher CJ. Development of a validated short-form of the childhood atopic dermatitis impact scale, the CADIS-SF15. J Eur Acad Dermatol Venereo. 2020;34(8):1773–8.

    Article  CAS  Google Scholar 

  71. Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the quality of life index for atopic dermatitis (QoLIAD). Br J Dermatol. 2004;150(2):274–83.

    Article  CAS  PubMed  Google Scholar 

  72. Eun H, Finlay AY. Measurement of atopic dermatitis disability. Ann Dermatol. 1990;2:9–12.

    Article  Google Scholar 

  73. Poindexter G, Monthrope Y, Shah N, Chen S. Pruritus quality of life instrument. J Am Acad Dermatol. 2005;52(3 Suppl 1):P106.

    Google Scholar 

  74. Saunderson RB, Harris V, Yeh R, Mallitt K, Fischer G. Vulvar quality of life index (VQLI) – a simple tool to measure quality of life in patients with vulvar disease. Australas J Dermatol [Internet]. 2020;61(2):152–7. https://doi.org/10.1111/ajd.13235.

    Article  PubMed  Google Scholar 

  75. Dreyfus I, Taïeb C, Barbarot S, Maza A, Galera I, Bourrat E, et al. IQoL-32: a new ichthyosis-specific measure of quality of life. J Am Acad Dermatol [Internet]. 2013;69(1):82–7. https://doi.org/10.1016/j.jaad.2013.01.022.

    Article  PubMed  Google Scholar 

  76. Augustin M, Conde Montero E, Zander N, Baade K, Herberger K, Debus ES, et al. Validity and feasibility of the wound-QoL questionnaire on health-related quality of life in chronic wounds. Wound Rep and Reg [Internet]. 2017;25(5):852–7. https://doi.org/10.1111/wrr.12583.

    Article  Google Scholar 

  77. Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073–8.

    Article  CAS  PubMed  Google Scholar 

  78. Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, et al. Development and validation of the cholinergic Urticaria quality-of-life questionnaire (CholU-QoL). Clin Exp Allergy [Internet]. 2018;48(4):433–44. https://doi.org/10.1111/cea.13102.

    Article  CAS  PubMed  Google Scholar 

  79. Ogunsanya ME, Cho SK, Hudson A, Chong BF. Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus. Br J Dermatol. 2019;180:1430–7. https://doi.org/10.1111/bjd.17636.

    Article  CAS  PubMed  Google Scholar 

  80. Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD-QoL: a quality of life measure specific to Behçet's disease. J Rheumatol. 2004;31(5):931–7.

    PubMed  Google Scholar 

  81. Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, et al. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy [Internet]. 2016;71(6):869–77. https://doi.org/10.1111/all.12842.

    Article  CAS  PubMed  Google Scholar 

  82. Burdon-Jones D, Gibbons K. The Skin Cancer Quality of Life Impact Tool (SCQOLIT): a validated health-related quality of life questionnaire for non-metastatic skin cancers. J Eur Acad Dermatol Venereol [Internet]. 2012;27(9):1109–13. https://doi.org/10.1111/j.1468-3083.2012.04669.x.

    Article  CAS  PubMed  Google Scholar 

  83. Vinding GR, Christensen KB, Esmann S, Olesen AB, Jemec GBE. Quality of life in non-melanoma skin cancer—the skin cancer quality of life (SCQoL) questionnaire. Dermatol Surg [Internet]. 2013;39(12):1784–93. https://doi.org/10.1111/dsu.12353.

    Article  CAS  PubMed  Google Scholar 

  84. Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plastic Surg [Internet]. 2006;8(5):314–8. https://doi.org/10.1001/archfaci.8.5.314.

    Article  Google Scholar 

  85. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1(1):53.

    Article  PubMed  Google Scholar 

  86. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D. IDI Multipurpose Psoriasis Research on Vital Experiences Study Group. Sensitivity of the dermatology life quality index to clinical change in patients with psoriasis. Br J Dermatol. 2003;149(2):318–22.

    Article  CAS  PubMed  Google Scholar 

  87. Kent G, al Abadie M. The psoriasis disability index—further analyses. Clin Exp Dermatol. 1993;18(5):414–6.

    Article  CAS  PubMed  Google Scholar 

  88. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672–6.

    Article  CAS  PubMed  Google Scholar 

  89. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol 2000;43(2 Pt 1):229–33.

    Google Scholar 

  90. McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. PharmacoEconomics. 2003;21(15):1069–79.

    Article  PubMed  Google Scholar 

  91. Tannus FC, Picosse FR, Soares JM, Bagatin E. Rosacea-specific quality of life questionnaire: translation, cultural adaptation and validation for Brazilian Portuguese. An Bras Dermato. 2018;93(6):836–42.

    Article  Google Scholar 

  92. McLellan C, Sisic M, Oon HH, Tan J. Preliminary validation of the HS-QoL: a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg [Internet]. 2017;22(2):142–6. https://doi.org/10.1177/1203475417736281.

    Article  PubMed  Google Scholar 

  93. Pinard J, Vleugels RA, Joyce C, Merola JF, Patel M. Hidradenitis suppurativa burden of disease tool: Pilot testing of a disease-specific quality of life questionnaire. J Am Acad Dermatol [Internet]. 2018;78(1):215–217.e2. https://doi.org/10.1016/j.jaad.2017.08.030.

    Article  PubMed  Google Scholar 

  94. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148(2):373–4.

    Article  CAS  PubMed  Google Scholar 

  95. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149(3):572–7.

    Article  CAS  PubMed  Google Scholar 

  96. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida ART, Rêgo VRPA, Mendes AMD, Filho JWA, Junqueira H. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006;156:13–20.

    Article  PubMed  Google Scholar 

  97. Swietlik J, Reeder M. Current quality-of-life tools available for use in contact dermatitis. Dermatitis. 2016;27(4):176–85.

    Article  CAS  PubMed  Google Scholar 

  98. Basra MK, Fenech R, Gatt RM, et al. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.

    CAS  PubMed  Google Scholar 

  99. ChrenMM LRJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–13.

    Article  Google Scholar 

  100. Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 2012;30(2):231–6, xiii.

    Google Scholar 

  101. Ramirez F, Chren MM, Botto N. A review of the impact of patch testing on quality of life in allergic contact dermatitis. J Am Acad Dermatol. 2017;75(5):1000–4.

    Article  Google Scholar 

  102. Ayala F, Nino M, Fabbrocini G, et al. Quality of life and contact dermatitis: a disease-specific questionnaire. Dermatitis. 2010;21(2):84–90.

    Article  PubMed  Google Scholar 

  103. Botto N, Raffi J, Trivedi M, Ramirez F, Allen IE, Chren M-M. Validating a quality-of-life instrument for allergic contact dermatitis. Dermatitis [Internet]. 2019;30(5):300–5. https://doi.org/10.1097/DER.0000000000000515.

    Article  PubMed  Google Scholar 

  104. Zampieron A, Buja A, Fusco M, Linder D, Bortune M, Piaserico S, Baldo V. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150(3):309–16. Epub 2014 Sep 18

    CAS  PubMed  Google Scholar 

  105. Reid EE, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol [Internet]. 2012 Mar;66(3):e97–102. https://doi.org/10.1016/j.jaad.2010.11.042.

    Article  PubMed  Google Scholar 

  106. Fischer TW, Schmidt S, Strauss B, Elsner P. Hairdex. Der Hautarzt [Internet]. 2001;52(3):219–27. https://doi.org/10.1007/s001050051293.

    Article  CAS  PubMed  Google Scholar 

  107. Buske-Kirschbaum A, Geiben A, Hellhammer D. Psychobiological aspects of atopic dermatitis: an overview. Psychother Psychosom. 2001;70(1):6–16.

    Article  CAS  PubMed  Google Scholar 

  108. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13–4.

    CAS  PubMed  Google Scholar 

  109. Shah N, Palubin K, Lucero M, Chen S. Measuring quality of life impact in patients with pruritus. J Am Acad Dermatol. 2005;52(3 Suppl 1):P105.

    Google Scholar 

  110. Love EM, Marrazzo GA, Kini S, Veledar E, Chen SC. ItchyQoL bands: pilot clinical interpretation of scores. Acta Derm Venereol. 2015;95(1):114–5.

    Article  PubMed  Google Scholar 

  111. Lockhart J, Gray NM. The development and evaluation of a questionnaire to assess the impact of vulval intraepithelial neoplasia: a questionnaire study. BJOG. 2013;120:1133–42.

    Article  CAS  PubMed  Google Scholar 

  112. Janda M, Obermair A, Cella D, et al. The functional assessment of cancer-vulvar: reliability and validity. Gynecol Oncol. 2005;97:568–75.

    Article  PubMed  Google Scholar 

  113. Hospital H. Self-assessment of sexual function and vaginal changes after. Psychooncology. 2004;13:577–92.

    Article  Google Scholar 

  114. Derogatis LR, Rosen R, Leiblum S, et al. The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women the female sexual distress scale (FSDS): initial validation of a standardized scale. J Sex Marital Ther. 2002;28:317–30.

    Article  PubMed  Google Scholar 

  115. Weinfurt KP, Lin L, Bruner DW, et al. Development and initial validation of the PROMIS sexual function and satisfaction measures version 2.0. J Sex Med. 2015;12:1961–74.

    Article  PubMed  Google Scholar 

  116. Froeding LP, Greimel E, Lanceley A, et al. Assessing patient-reported quality of life outcomes in vulva cancer patients: a systematic literature review. Int J Gynecol Cancer. 2018;28:808–17.

    Article  PubMed  Google Scholar 

  117. Blome C, Baade K, Sebastian Debus E, Price P, Augustin M. The “wound-QoL”: a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen [Internet]. 2014;22(4):504–14. https://doi.org/10.1111/wrr.12193.

    Article  PubMed  Google Scholar 

  118. Ferreira PL, Gonçalo M, Ferreira JA, Costa AC, Todo-Bom A, Abreu CL, et al. Psychometric properties of the Portuguese version of the chronic urticaria quality of life questionnaire (CU-Q2oL). Health Qual Life Outcomes [Internet]. 2019;17(1). doi: https://doi.org/10.1186/s12955-019-1266-y.

  119. Dias GAC, Pires GV, Valle SOR, França AT, Papi JA, Dortas SD Jr, et al. Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire - CU-Q2oL. Allergy [Internet]. 2011 Sep 8;66(11):1487–93. https://doi.org/10.1111/j.1398-9995.2011.02695.x.

    Article  CAS  PubMed  Google Scholar 

  120. Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M. Clinical measures of chronic Urticaria. Immunol Allergy Clin N Am. 2017;37(1):35–49.

    Article  Google Scholar 

  121. (EMEA) EMA, (CHMP) CFMPFHU. reflection paper on the regulatory guidance for the use of health-related quality of life (hrql) measures in the evaluation of medicinal products; 2006. http://www.emaeuropaeu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637pdf. Doc. Ref. EMEA/CHMP/EWP/139391/2004. Accessed April 2017.

  122. (FDA) USDoHaHSFaDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims; 2009. https://www.fdagov/downloads/drugs/guidances/ucm193282.pdf. Accessed April 2017

  123. Mlynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, et al. The German version of the chronic Urticaria quality-of-life questionnaire: fator analysis, validation, and initial clinical findings. Allergy. 2009;64(6):927–36.

    Article  CAS  PubMed  Google Scholar 

  124. Weller K, Magerl M, Peveling-Oberhag A, Martus P, Staubach P, Maurer M. The angioedema quality of life questionnaire (AE-QoL)—assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016;71(8):1203–9.

    Article  CAS  PubMed  Google Scholar 

  125. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy [Internet]. 2012;67(10):1289–98. https://doi.org/10.1111/all.12007.

    Article  CAS  PubMed  Google Scholar 

  126. Vasquez R, Wang D, Tran QP, ail. A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. Br J Dermatol. 2013;168:145–53.

    Article  CAS  PubMed  Google Scholar 

  127. Foering K, Goreshi R, Klein R, et al. Prevalence of self-report photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol. 2012;66:220–8.

    Article  PubMed  Google Scholar 

  128. Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;64:849–58.

    Article  PubMed  Google Scholar 

  129. Mendez-Flores S, Orozco-Topete R, Bermudez-Bermejo P, Hernandez-Molina G. Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity. Clin Exp Rheumatol. 2013;31:940–2.

    PubMed  Google Scholar 

  130. Ogunsanya ME, Kalb SJ, Kabaria A, Chen S. A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus. Br J Dermatol. 2017;176(1):52–61. https://doi.org/10.1111/bjd.14868. Epub 2016 Dec 7.

    Article  CAS  PubMed  Google Scholar 

  131. Ogunsanya ME, Brown CM, Lin D, et al. Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus (CLE): a qualitative study. Int J Womens Dermatol. 2018;4:152–8.

    Article  CAS  PubMed  Google Scholar 

  132. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol. 1996;14(2):671–9.

    Google Scholar 

  133. Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the US Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;20:7–9.

    Google Scholar 

  134. Hernyshov PV, Lallas A, Tomas-Aragones L, Arenbergerova M, Samimi M, Manolache L, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European academy of dermatology and venereology task forces on quality of life and patient oriented outcomes, melanoma and non-melanoma skin cancer. J Eur Acad Dermatol Venereol [Internet]. 2019;33(5):816–27. https://doi.org/10.1111/jdv.15487.

    Article  Google Scholar 

  135. Lee EH, Klassen AF, Nehal KS, Cano SJ, Waters J, Pusic AL. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. J Am Acad Dermatol [Internet]. 2013;69(2):e59–67. https://doi.org/10.1016/j.jaad.2012.09.017.

    Article  PubMed  Google Scholar 

  136. Rhee JS, Davis-Malesevich M, Logan BR, Neuburg M, Burzynski M, Nattinger AB. Behavior modification and risk perception in patients with nonmelanoma skin cancer. WMJ. 2008;107:62–8.

    PubMed  Google Scholar 

  137. Bech P. Quality of life measurement in the medical setting. Eur Psychiatry. 1995;10:83–5.

    Article  Google Scholar 

  138. Loney T. Psychosocial effects of dermatological-related social anxiety in a sample of acne patients. J Health Psychol. 2008;13(1):47–54.

    Article  PubMed  Google Scholar 

  139. Capoore HS, et al. Does psychological intervention help chronic skin conditions? Postgrad Med J. 1998;74:662–4.

    Article  CAS  PubMed  Google Scholar 

  140. Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66(Suppl 1):34–40.

    Article  CAS  PubMed  Google Scholar 

  141. Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014;31(3):309–18.

    Article  PubMed  Google Scholar 

  142. Eismann EA, Lucky AW, Cornwall R. Hand function and quality of life in children with epidermolysis bullosa. Pediatr Dermatol. 2014;31(2):176–82.

    Article  PubMed  Google Scholar 

  143. Klatchoian DA, et al. Qualidade de vida de crianças e adolescentes de São Paulo: confiabilidade e validade da versão brasileira do questionário genérico Pediatric quality of life inventory TM versão 4.0. J Pediatr. 2008;84(04):308–25.

    Article  Google Scholar 

  144. Scarpelli AC, et al. The pediatric quality of life inventory™ (PedsQL™) family impact module: reliability and validity of the Brazilian version. Health Qual Life Outcomes. 2008;6:35–42.

    Article  PubMed  Google Scholar 

  145. Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126–39.

    Article  CAS  PubMed  Google Scholar 

  146. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the dermatitis family impact questionnaire. Br J Dermatol. 1998;138:107–13.

    Article  CAS  PubMed  Google Scholar 

  147. Manificat S, Dazord A. Évaluation de la qualité de vie de l’enfant: validation d’un questionnaire, premiers résultats. Neuropsychiatr Enfance Adolesc. 1997;45:106–14.

    Google Scholar 

  148. Prati C, Comparin C, Boza JC, Cestari TF. Validação para o português falado no Brasil do instrumento Escore da Qualidade de Vida na Dermatologia Infantil (CDLQI). Med Cutan Iber Lat Am. 2010;38:229–33.

    Google Scholar 

  149. Weber MB, Lorenzini D, Reinehr CPH, Lovato B. Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras Dermatol. 2012;87(5):697–702.

    Article  PubMed  Google Scholar 

  150. Basra MKA, Salek MS, Fenech D, Finlay AY. Conceptualization, development and validation of T-QoL © (teenagers’ quality of life): a patient-focused measure to assess quality of life of adolescents with skin diseases. Br J Dermatol [Internet]. 2017;178(1):161–75. https://doi.org/10.1111/bjd.15853.

    Article  PubMed  Google Scholar 

  151. McKenna SP, Whalley D, Dewar AL, Erdman RA, Kohlmann T, Niero M, Baró E, Cook SA, Crickx B, Frech F, van Assche D. International development of the parents’ index of quality of life in atopic dermatitis (PIQoL-AD). Qual Life Res. 2005;14(1):231–41.

    Article  PubMed  Google Scholar 

  152. Chamlin SL, Cella D, Frieden IJ, Williams ML, Mancini AJ, Lai JS, Chren MM. Development of the childhood atopic dermatitis impact scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J Invest Dermatol. 2005;125:1106–11.

    Article  CAS  PubMed  Google Scholar 

  153. Eghlileb AM, Basra MKA, Finlay AY. The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis. Dermatology. 2009;219:63–70.

    Article  CAS  PubMed  Google Scholar 

  154. Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P. The PedsQL family impact module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55. https://doi.org/10.1186/1477-7525-2-55.

    Article  PubMed  Google Scholar 

  155. Basra MKA, Sue-Ho R, Finlay AY. Family dermatology life quality index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156:528–38. Erratum. Br J Dermatol. 2007;156:791.

    Google Scholar 

  156. Weber MB, Fontes Neto PT, Prati C, Soirefman M, Mazzotti NG, Barzenski B, et al. Improvement of pruritus and quality of life of children with atopic dermatitis and their families after joining support groups. JEADV. 2008;22:992–9.

    PubMed  Google Scholar 

  157. Dodington SR, Basra MK, Finlay AY, Salek MS. The dermatitis family impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol. 2013;169(1):31–46.

    Article  CAS  PubMed  Google Scholar 

  158. Lewis-Jones MS, Dawe RS, Lowe JG. Quality of life in children with type 1 latex allergy and their parents: use and primary validation of the QoLLAC and QoLLA-P questionnaires. Br J Dermatol. 2005;153(Suppl 1):83–4.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology Service of Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil

    Magda Blessmann Weber, Mariele Bevilaqua & Gustavo Bottene Ribolli

  2. São Bernardo do Campo, São Paulo, Brazil

    Rebeca Kollar Vieira da Silva

Authors
  1. Magda Blessmann Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariele Bevilaqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebeca Kollar Vieira da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gustavo Bottene Ribolli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dermatology Service, Federal University of Rio Grande do Sul/HCPA, Porto Alegre, Rio Grande do Sul, Brazil

    Renan Rangel Bonamigo

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Weber, M.B., Bevilaqua, M., da Silva, R.K.V., Ribolli, G.B. (2023). Quality of Life in Dermatology. In: Rangel Bonamigo, R. (eds) Dermatology in Public Health Environments. Springer, Cham. https://doi.org/10.1007/978-3-031-13505-7_61

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-13505-7_61

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-13504-0

  • Online ISBN: 978-3-031-13505-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation